Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
WALTHAM, Mass., Aug. 24, 2017 -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Company Management will be presenting at three upcoming conferences in September 2017.
- Baird 2017 Global Healthcare Conference – New York, NY (September 6-7, 2017)
Jonathan Lieber, Chief Financial Officer of Histogenics, will be presenting a corporate overview on Thursday, September 7 at 10:15 AM EDT. The conference will be held at the InterContinental New York Barclay in New York City. The presentation will be webcast live and may be accessed by visiting the Investor Relations section of Histogenics’ website at www.histogenics.com. The webcast will be archived and available on Histogenics’ website for 45 days following the conferences. - 19th Annual Rodman & Renshaw Global Investment Conference – New York, NY (September 10-12, 2017)
Jonathan Lieber, Chief Financial Officer of Histogenics, will be presenting a corporate overview on Monday, September 11 at 10:00 AM EDT. The conference is sponsored by H.C. Wainwright & Co., LLC., and will be held at the Lotte New York Palace Hotel in New York City. The presentation will be webcast live and may be accessed by visiting the Investor Relations section of Histogenics’ website at www.histogenics.com. The webcast will be archived and available on Histogenics’ website for 45 days following the conferences. - Healthcare Capital & Connections Summit – Shanghai, China (September 12-14, 2017)
Adam Gridley, President and Chief Executive Officer of Histogenics, will be presenting a corporate overview on Wednesday, September 13 at 2:00 PM local time. The conference is sponsored by Silicon Valley Bank, AdvaMed Accel, Piper Jaffray and Vivo Capital and will be held at the InterContinental Ruijin in Shanghai.
About Histogenics Corporation
Histogenics is a leading regenerative medicine company developing and commercializing novel tissue therapies that may offer more rapid and durable recoveries for patients with pain and loss of function due to musculoskeletal conditions. Histogenics’ regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering and bioadhesives to create tissue ex-vivo. Histogenics’ first investigational product candidate, NeoCart is designed to treat cartilage defects in the knee. The Company recently completed enrollment of its NeoCart Phase 3 clinical trial and expects to report top-line data in the third quarter of 2018. NeoCart is designed to exhibit characteristics of articular, hyaline cartilage prior to and upon implantation into the knee and therefore does not rely on the body to make new cartilage. As a result, NeoCart is the only product in development or on the market with a one-year primary superiority endpoint as compared to the standard of care. There are more than 500,000 or more knee cartilage procedures in the United States each year, with many healthy active adults avoiding treatment as they seek other alternatives. Left untreated, even a small cartilage defect can expand in size and progress to debilitating osteoarthritis, ultimately necessitating a joint replacement procedure. Osteoarthritis is more common in adults over the age of 50, but the condition and precursors of the condition can be observed much earlier, and cartilage damage is believed to be one of the leading contributors of this disease. For more information, please visit www.histogenics.com.
Contact: Investor Relations Tel: +1 (781) 547-7909 [email protected]
